Curevac announces financial results for the second quarter and first half of 2024 and provides business update

Closed new licensing agreement with gsk worth up to €1.45 billion, including €400 million upfront; provides strong validation of curevac's mrna platform initiated strategic workforce reduction of ~30% by end of 2024, optimizing business to focus on high-value opportunities in oncology, infectious diseases and other areas invoiced €10 million milestone payment after phase 2 transition of pre-pandemic avian influenza (h5n1) program; candidate fully licensed to gsk under new agreement dosing of first patient in phase 1 study part b in glioblastoma with cvgbm to establish dose-confirmation; initial dose-escalation part a data accepted for oral presentation at esmo strengthening of supervisory board with appointment of innovation expert birgit hoffman and clinical oncologist mehdi shahidi, m.d. chief financial officer, pierre kemula, to step down at the end of his term october 31, 2024; search for a replacement ongoing with transition plan in place cash and cash equivalents position of €202.5 million as of june 30, 2024, not including €400 million upfront payment from gsk agreement; reaffirming cash runway into 2028 tÜbingen, germany and boston, ma / accesswire / august 15, 2024 / curevac n.v.
CVAC Ratings Summary
CVAC Quant Ranking